LN-229細(xì)胞
數(shù)量： 大量
細(xì)胞形態(tài)： 上皮樣
器官來源： 大腦
生長狀態(tài)： 貼壁生長
ATCC Number： CRL-2611?
相關(guān)**： 其他**
組織來源： right frontal parieto-occipital cortex
是否是腫瘤細(xì)胞： 0
物種來源： 人
運(yùn)輸方式： 凍存運(yùn)輸
年限： 60 years
Designations: LN-229
Depositors: N de Tribolet
LN-229細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens deposited as human
Morphology: epithelial
Source: Organ: brain
Tissue: right frontal parieto-occipital cortex
Disease: glioblastoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: 1979
Tumorigenic: Yes
LN-229細(xì)胞Oncogene: p53 + (mutated, CCT (Pro) --> CTT (Leu) mutation at codon 98), PTEN + (wild type), p16 - (deleted), p14ARF - (deleted)
DNA Profile (STR): Amelogenin: X
CSF1PO: 12
D13S317: 10,11
D16S539: 12
D5S818: 11,12
D7S820: 8,11
THO1: 9.3
TPOX: 8
vWA: 16,19
Age: 60 years
Gender: female
Ethnicity: White
Comments: The cells exhibit mutated p53 (TP53) and possible homozygous deletions in the p16 and p14ARF tumor suppressor genes. They have a wild-type PTEN gene. LN-229細(xì)胞[51573]
The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987]. [51573]
Stimulation of the cells with Fas ligand lead to apoptotic cell death within 16 hours. The cells were also killed by puromycin in a dose dependent manner. [53380]
Bcl-2 protects these cells from Fas ligand-induced cell death but was shown to have only a small protective effect on puromycin-induced apoptosis. [53380]
This cell line is used in studies on apoptosis.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 5%.
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: LN-229細(xì)胞To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 51571: Diserens AC, et al. Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol. 53: 21-28, 1981. PubMed: 7211194
51573: Ishii N, et al. LN-229細(xì)胞Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9: 469-479, 1999. PubMed: 10416987
53380: Schlapbach R, Fontana A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells.. Biochim. Biophys. Acta 1359: 174-180, 1997. PubMed: 9409814
